The use of vaccines in the prevention and treatment of cervical cancer.
The close association between high risk HPV infection and cervical carcinoma has provided the impetus for the development of prophylactic and therapeutic vaccination schedules. An effective prophylactic vaccine would obviate the need for population-based cervical screening programmes, while therapeutic vaccination might provide an effective adjunct to or replacement for conventional treatment for benign and malignant cervical disease. While the challenges associated with the design and implemention of immunotherapies are numerous, optimism remains high and it is expected that the next few decades will witness a revolutionary change in the way we treat cervical cancer and its premalignant lesions. A papillomavirus vaccine that prevented HPV infection on the one hand and acted against established disease on the other, would have a profound impact on one of the major cancers affecting women globally.
Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK. edavidson@picr.man.ac.uk
Emma J
EJ
Davidson
Henry C
HC
Kitchener
Peter L
PL
Stern
D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D014412:Tumor Virus Infections / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000517:prevention & control / Q000628:therapy* / Q000821:virology; D014765:Viral Vaccines / Q000627:therapeutic use*
D019496:Cancer Vaccines; D014765:Viral Vaccines